More importantly, a PTK7-targeting antibody-drug conjugate (ADC) induced sustained tumor regressions in lung and breast tumor xenograft models (12); furthermore, recent studies have documented the success and feasibility of PTK7-based tumor-targeting strategies by using PTK7-specific antibodies or aptamers for in vivo imaging or drug delivery (23–25). Here, PTK7 is linked to neoplasm.